Vaxart Announces Positive Pre-Clinical Data for its Oral COVID-19 Vaccine ProgramGlobeNewsWire • 04/21/20
VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATEGlobeNewsWire • 03/18/20
EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASEGlobeNewsWire • 03/18/20
Vaxart Announces $10.0 Million Registered Direct Offering Priced At-the-MarketGlobeNewsWire • 02/27/20